Testicular germ cell tumor is rare in the Asian population. Nevertheless, it is a prototypic cancer of young adults because it can be highly malignant but is also highly curable, even at an advanced stage. We present a case with far-advanced embryonal carcinoma, treated with bleomycin, etoposide and platinum (BEP) × 4 cycles. This case has shown very good results from the treatment. This is the standard therapy for poor-and intermediate-risk patients with germ cell tumors in the advanced stage, supported by current evidence-based literature. BEP × 3 cycles or EP × 4 cycles is the standard therapy for good-risk patients with advanced germ cell tumors. Using these treatments, we can achieve durable remissions of approximately 90%, 75%, and 45% in good-, intermediate-, and poor-risk patients, respectively. However, the physical and psychological long-term outcomes should be carefully monitored. [J Chin Med Assoc 2010;73(7):343-352] 
Introduction
Testicular germ cell tumor (TGCT) is a prototypic cancer of young adults. It can be highly malignant, but is also highly curable (approximately 80%), even at an advanced stage, with modern therapy. TGCT is rare in the Asian population, but is the most common malignancy in adolescent and young adult males aged 15-35 years in Western countries. The age-standardized incidence rate worldwide is approximately 1.5/100,000 with substantial variations between countries. 1 It is more common in Caucasians and its incidence has increased. 2 TGCTs are rare in African and Asian populations, even after migration. 3 Only a few cases have been reported in Taiwan. 4 It has been emphasized that it should be managed by an experienced team. We discuss the experience of TGCTs in the USA and Taiwan and present a case with current evidence-based medicine (EBM) illustration (Table 1) . We also discuss how to treat this potentially curable disease.
Case Illustration
A 17-year-old male student visited the genitourinary clinic in early June 2008 due to the new onset of painful swelling of the left scrotum. He was treated with different antibiotics without a response with suspected left epididymitis. The patient had lost 20 kg (89 kg down to 69 kg) in 6 months. Physically, he had swollen left scrotal content with tenderness and local heat without palpable inguinal lymph nodes. Laboratory tests showed negative urinalysis, but there was leukocytosis (12,070/μL). Computed tomography (CT) of the abdomen and pelvis performed on August 22, 2008 showed an enhanced left testicular mass (2.3 cm) with heterogeneous density, multiple left para-aortic and inguinal lymph nodes (the largest was 2 cm), and multiple hepatic tumors in both lobes (the largest was 9 cm) ( Figure 1A ). Further laboratory tests revealed mild elevation of serum aspartate aminotransferase levels (37 IU/L) and substantial elevations of lactic
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Evidence-based Treatment for Advanced Germ Cell
Tumor of the Testis With a Case Illustration dehydrogenase (LDH) (2,189 IU/L), β-human chorionic gonadotropin (HCG) (26.5 mIU/mL), and α-fetoprotein (AFP) (371 ng/mL) levels (Table 2) . Based on the CT findings, left orchiectomy with left inguinal lymph node dissection was performed on August 25, 2008 . Pathology showed embryonal carcinoma of the left testis and negative inguinal lymph node involvement. Medical oncologists started to be involved in the patient's care from August 28, 2008 . After reviewing the pathology, we discussed in detail the prognosis, goals of treatment and preparations before chemotherapy with the patient and his family.
Preparation
The patient's family had requested 2 nd and 3 rd opinions from 2 other major tertiary medical centers, and both gave advice similar to ours. Therefore, they decided to stay at our hospital for treatment. We gave them a detailed treatment plan. The patient had a port-A catheter inserted by a general surgeon for future chemotherapy. He also had a pulmonary function test, which revealed normal results before bleomycin treatment. 5 He also had sperm preservation before starting chemotherapy (EBM level 3b). 6 
Staging
The patient's pathology was embryonal carcinoma, one of the nonseminomatous germ cell tumors (NSGCTs) without a teratoma element. During the preparation period, he developed severe lower back pain without evidence of spinal cord compression by neurosurgical evaluation. A bone scan was negative for bone metastasis. He required constant narcotic medication. We believe that this was due to progressive retroperitoneal lymph node enlargement (because his pain subsided after the 1 st chemotherapy). His liver was also enlarged, with tenderness on examination. LDH levels were elevated to 4,805 IU/L before the beginning of treatment. In addition, bilateral pulmonary metastases were shown on a CT scan, as well as liver metastases as mentioned above. Therefore, the patient was diagnosed as stage IIIC (T 2 N 1 M 1b S 3 ) (Table 3) 7 and in the poorrisk group (Table 4) . 
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Treatment for advanced testicular germ cell tumor Lymph node mass ≤ 2 cm in greatest dimension or multiple lymph nodes, none > 2 cm in greatest dimension. N2 Lymph node mass > 2 cm but not > 5 cm in greatest dimension, or multiple lymph nodes, any 1 mass > 2 cm but not > 5 cm in greatest dimension.
N3
Lymph node mass > 5 cm in greatest dimension.
Metastasis
M0
No distant metastasis.
M1a
Nonregional lymph node or pulmonary metastasis.
M1b
Distant metastasis other than to nonregional lymph nodes and lungs.
Tumor markers (serum) S0 Markers within normal limits. S1
LDH < cisplatin 20 mg/m 2 daily × 5 (BEP) due to high-risk stage IIIC (EBM levels 1b 10,12-14 and 2b 11 ). [9] [10] [11] [12] [13] [14] The chemotherapy began on September 11, 2008 and finished on November 28, 2008 , and the patient responded well. He received the full doses on a set schedule 9 with supplement of granulocyte-colony stimulating factor (G-CSF) in all cycles (EBM level 2a). 15 His absolute neutrophil count dropped to 288/μL on day 12 after the 1 st cycle of chemotherapy was complicated with acute tonsillitis. All tumor markers returned to normal before the 3 rd cycle of chemotherapy (Table  2 ; EBM levels 2b 17 and 3b 16 ). 16, 17 Follow-up CT of the chest on October 22, 2008 revealed total disappearance of the pulmonary metastases. The patient's retroperitoneal lymph nodes also regressed in December 2008, but his liver lesions remained in both lobes, with the largest being 2.4 cm. We decided that he could not have post-chemotherapy resection due to multiple lesions in both lobes of the liver (EBM levels 2b, 20 3a, 21 and 3b 18, 19, 22 ). [18] [19] [20] [21] [22] Instead, he underwent CTguided biopsy of the largest liver lesion, which showed marked tumor necrosis with focal fibrosis.
Problems, intervention, and outcome
The main problem of the presented case was stage IIIC NSGCT belonging to the high-risk group. 7, 8 There are many different chemotherapy regimens for TGCT. Based on the above evidence-based literature, our patient received BEP × 4 of the original 5-day regimen (EBM levels 1b 10, [12] [13] [14] 23 and 2b 11 ), [9] [10] [11] [12] [13] [14] 23 without compromising the dose or delaying the schedule. This is the standard treatment for high-risk NSGCT in stage IIIC. He had an excellent response and is still in complete remission according to the latest physical examination, tumor markers (EBM levels 2b 17 and 3b 16 ) 16, 17 ( Table 2 ) and imaging studies ( Figure 1B ). Another problem was severe neutropenia with acute tonsillitis after the 1 st cycle of chemotherapy. This was a complication from the treatment. In general, prophylactic G-CSF is not indicated. In this case, because of the infection with severe neutropenia, the patient received G-CSF in each cycle. He was able to keep his chemotherapy schedule on time and without compromising the dose (EBM level 2a 15 ). 9, 15 There were no further infectious complications. This was considered to be a successful key point. However, we needed to decide whether the patient should have laparotomy to resect the residual masses shown on CT after 4 cycles of BEP. This is a controversial issue (EBM levels 2b, 20 3a 21 and 3b 18, 19, 22 ). [18] [19] [20] [21] [22] 24 His retroperitoneal lymph nodes were nearly gone (< 1 cm) and pulmonary lesions had completely disappeared. The lesions were present in both lobes of the liver, which could not be resected completely unless there was an intention to have a liver transplant. The patient had no teratoma elements in the initial pathology, which made the possibility of teratoma of these residual masses less likely. Therefore, he had CT-guided biopsy to the largest liver lesion instead of laparotomy resection. Other major symptoms and signs were weight loss, severe pain, hepatomegaly and marked elevation of tumor markers. These all resolved after treatment.
Follow-up
The serial follow-up of tumor markers was normal (Table 2 ). In July 2009, a thymic tumor was suspected from CT of the chest. Video-assisted thoracic surgical resection of the thymus was performed, and the pathology revealed only thymic hyperplasia without evidence of tumor recurrence. CT of the chest, abdomen ( Figure 1B ) and pelvis revealed no evidence of active disease. The patient is currently in complete remission as shown by normal tumor markers, even though there were residual liver lesions shown on CT that were necrotic, and fibrotic tissue on biopsy. Continued follow-up for relapse and late relapse 25, 26 (EBM level 3b). Long-term complications related to the BEP regimen are also future possibilities (EBM levels 3a 27 and 3b [28] [29] [30] ).
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Biology, Pathology and Staging
Biology
Recent gene expression profiling studies of TGCTs along with advances in embryonic stem-cell research have contributed to understanding the biology of the disease. Gain of the short arm of chromosome 12 detected in almost all adult germ cell tumors (GCTs) appears to be malfunctional in germ cell tumorigenesis, based on the observed overexpression of genes mapped to this region involved in maintaining pluripotency and oncogenesis.
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Pathology
GCTs are classified into 2 broad histological categories: seminomatous and nonseminomatous GCT. Patients with seminoma who have increased AFP levels or any of the NSGCT components (including teratoma) are considered to have a NSGCT. NSGCT is further divided into 4 types as follows. 1 (1) Embryonal carcinoma is composed of large pleomorphic cells with different architectural patterns. It is the most undifferentiated cell type. This tumor may be associated with an elevation of HCG and/or AFP serum levels, as in our case. (2) Endodermal sinus tumor (yolk sac carcinoma) is the most common testicular tumor seen in infants and young children. It is uncommon in the adult testis but accounts for a significant percentage of primary mediastinal NSGCT. It has a variety of architectural patterns. Yolk sac tumor mimics the yolk sac of the embryo, producing AFP. (3) Choriocarcinoma, as a pure entity, is one of the least common GCTs. These tumors have a great propensity for hematogenous spread, often skipping the retroperitoneum. It is associated with an elevated serum level of HCG. (4) Teratoma is generally a benign tumor with elements from 2 or more of the germ layers (ectoderm, mesoderm, and the endoderm). Teratoma is uncommonly seen as the sole histology in primary tumors, but it is frequently associated with other histological elements mentioned above. Serum markers are normal in patients with pure teratoma.
Prognostic classification
GCTs are spread by both lymphatic and vascular channels. Prognosis is related not only to the anatomic extent of the spread but also to the primary site and the extent of production of the tumor markers (EBM level 3b). 32 These features incorporate several prognostic factor classifications of widely differing types and complexity, and it is difficult to compare between different classifications (EBM level 3b). 33 As a result, the International Germ Cell Cancer Collaborative Group (IGCCCG) was formed in 1991. Members agreed to pool clinical data on a large population of patients with metastatic GCT. An agreed prognostic factor classification for use in clinical practice and future trials has resulted from this collaboration. A consensus classification was defined (poor, intermediate, and good) and published in 1997 (Table 4) . 8 The American Joint Committee on Cancer adopted this classification in its staging manual beginning from the 6 th edition (Table 3) . 
Good-risk GCT
After trials in the late 1970s and early 1980s, the curability of metastatic GCT was established. Strategies were then necessary to decrease the toxicity resulting from therapy. Elimination of bleomycin, substitution of carboplatin for cisplatin, and a reduced number of chemotherapy cycles were studied systematically (EBM level 1b). [34] [35] [36] The results of phase 3 randomized trials showed that carboplatin was inferior to cisplatin in combination with etoposide (EBM level 1b). 36, 37 In contrast, bleomycin could be eliminated from therapy when 4 cycles of etoposide plus cisplatin had been administered (EBM level 1b). 38 Bleomycin toxicity remains an important issue in good-risk patients. 5 Acute pulmonary toxicity is reduced with BEP × 3 (EBM level 3b 39 ). 5, 39 Moreover, long-term cardiovascular diseases are now recognized in connection with BEP therapy (EBM level 3b). 28, 40 Raynaud's phenomenon is reported to occur in 6-24% of patients (EBM level 1b). 35 Therefore, a randomized trial comparing BEP × 3 with EP × 4 was designed. It was concluded that the regimen of EP × 4 is an alternative to BEP × 3 in good-risk GCT (EBM levels 1b 41 and 3a 42 ). 41, 42 In addition, the drug dose was determined to be crucial, as survival was superior with an etoposide 500 mg/ m
Poor-and intermediate-risk GCT
Of patients with metastatic disease, 20-30% appear to be more resistant to initial treatment. Hoping for a better response, double-dose cisplatin and other doseescalation regimens, as well as alternating and sequential regimens, have been tried, but they did not improve on the standard BEP × 4 (EBM levels 1b 13, 14 and 2b 11 ). 11, 13, 14 In a randomized trial comparing BEP × 4 versus VP-16 plus ifosfamide plus platinum (VIP) × 4, the response rates and survival were comparable, but VIP had more hematological toxicity (EBM level 1b).
10 VIP can be offered as an alternative therapy for patients with compromised pulmonary function or other pre-existing conditions precluding treatment with the standard BEP regimen (EBM level 1b). 12 Another randomized trial compared BEP × 4 with BEP × 2 followed by high-dose therapy (carboplatin, etoposide and cyclophosphamide with autologous stem-cell rescue) and showed no difference in outcome (EBM level 1b). 23 Chemotherapy should be given without dose reduction at 21-day intervals. Dose reduction is highly discouraged, even in the setting of a critically-ill patient. 9 Postponing treatment (a maximum of 3 days for each decision) should rarely be considered. For example, in cases of existing fever, with a neutrophil count < 500/μL or platelet counts < 10,000/μL at day 1 of a subsequent cycle, 9 there is no indication for routine prophylactic use of hematopoietic growth factors such as G-CSF (EBM level 2a). 43 However, if serious infections have occurred during 1 preceding chemotherapy cycle, as in the presented case, prophylactic application of G-CSF is recommended in subsequent cycles to maintain the required dose intensity (EBM level 2a). 15 The original 5-day BEP regimen for 4 cycles is standard in intermediateand poor-risk GCT. 9 Approximately 10% of all patients with advanced GCT (i.e. 1-2% of all GCTs) present with brain metastases. These patients have a long-term survival of 30-40%, whereas patients who develop brain metastases with other metastases during first-line therapy have a 5-year survival rate of only 2-5% (EBM level 3b). 44 
Monitoring treatment results
Tumor markers and imaging studies are the 2 major tests to monitor the treatment results of GCT (EBM level 2a). 45 The frequency and type of examinations depend on the estimated risk of relapse, the chosen treatment strategy, and the time elapsed since the completion of treatment and should be modified according to their risks. It is important that the markers be measured directly before each treatment cycle, otherwise, the markers can be falsely increased due to release from necrotic tumor cells. 9 A tumor marker (HCG, AFP, and LDH) surge was noted in the very first few weeks after initiation of chemotherapy (EBM level 2b). 17 After the transient elevation, the rate of decline of HCG (half-life, 18-36 hours) and AFP (half-life, 5-7 days) has a prognostic impact on both progressionfree survival and overall survival, especially in patients with a poor prognosis, as seen in this case (EBM level 3b 16 ). 16, 46 After normalization of these markers, they should be followed more frequently at the beginning of treatment and less often later on. The same principle applies to imaging studies. In patients with a slow marker decline or clinical evidence of progression, radiological restaging should be considered (EBM level 3b). 47 The images should include CT of the abdomen and pelvis with contrast and other organs of initial involvement. Positron emission tomography scans are very useful in seminoma patients for residual disease evaluation (EBM level 2b). 48 However, they are not sensitive enough for NSGCT (EBM levels 2b 49 and 3b 50 ). 49, 50 Progression with tumor markers despite firstline chemotherapy requires the immediate initiation of salvage treatment (EBM levels 2b 17 and 3b 51 ).
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Resection of residual masses should be performed in patients with tumor markers persisting at low levels after completion of first-line treatment (EBM level 2b).
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Resection of residual tumor Seminoma
In patients with seminoma, residual masses present after chemotherapy and after radiotherapy should not be resected, but should be closely followed by tumor marker determinations and imaging studies (EBM level 4). 53 Fluorodeoxyglucose-positron emission tomography has a prognostic value in this situation, especially with residual lesions > 3 cm. If the result is negative, no resection or any other treatment is necessary. If the result is positive, histology should be obtained by biopsy or preferably by resection (EBM level 2b). 48 Further treatment should be based on the results of histology and may include observation, radiation, or further chemotherapy (EBM level 3b). 54 
Nonseminoma
Patients with nonseminoma who achieve serologic complete remission (normalization of all tumor markers) will have either complete regression of radiographic abnormalities or persistent radiographic masses. No post-chemotherapy surgery is required in the former situation; there is significant controversy with regard to the latter situation (EBM level 3b). 19 Patients who are initially teratoma-negative and who have more than 90% radiological regression can be followed closely without resection. However, surgical resection is another option (EBM level 3b). 22 In all other situations, all residual masses should be resected if technically feasible (EBM level 3b 18 ). 18, 24 Histology of residual masses after first-line chemotherapy shows necrosis (50%), mature teratoma (35%), and vital cancer (15%) (EBM levels 2b 20 and 3a 21 ). 20, 21 Complete resection of residual teratomas is important because it may progress to obstruct or invade adjacent structures, and is associated with a malignant transformation risk and higher rate of late relapse.
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Consolidation chemotherapy after secondary surgery
If the resection histology shows necrosis or teratoma, no further treatment is required. When a viable undifferentiated tumor is found from resection, the role of consolidation chemotherapy is uncertain (EBM level 3b). 18 If > 10% of viable cancer is found, or if completeness of the resection is in doubt, consolidation chemotherapy might be justified.
Salvage chemotherapy for relapsed or refractory disease
In patients who relapse or progress after first-line chemotherapy, prognostic indicators are the localization and histology of the primary tumor, response to firstline treatment, duration of previous remissions, and the levels of tumor markers (EBM level 2b). 55 Caution should be used when suspicion of relapse is based on elevations in tumor markers only. Elevation of AFP can occur from lab errors, hepatoma or liver inflammation. False elevation of HCG may occur in patients who use marijuana, and there is some cross-reactivity in the radioimmunoassay with luteinizing hormone. 56 The common regimens in second-or third-line chemotherapy are paclitaxel plus ifosfamide plus cisplatin (TIP), 57 VIP, 10 vinblastin plus ifosfamide plus cisplatin (VeIP) 58, 59 or high-dose chemotherapy.
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Late relapse
A late relapse is defined as any disease recurrence more than 2 years after completing first-line treatment, and was not recognized before 1983. A pooled analysis of a large series published between 1989 and 2006 showed a crude incidence of 3.2% for nonseminoma and 1.4% for seminoma (EBM levels 3a 25 and 3b 26 ). 25, 26, 62 The most important observation on late relapse in patients who have received cisplatin-based combination chemotherapy is that surgical resection of all recurrent disease is important in determining outcome. This is due to relative resistance to chemotherapy, but is also due to the frequency of teratoma within the recurrence (EBM levels 3a 25 and 3b 26 ). 25, 26, 62 If the lesions are not completely resectable, biopsies should be obtained for histological assessment and salvage chemotherapy should be initiated according to the histological results.
Follow-up, late effects, and psychosocial impact
The aims of follow-up of patients with GCT are detection of relapse, diagnosis of second cancers and their prevention, and treatment of physical and psychological modalities related to GCT or its treatment. Given the long life expectancy of this young patient population, evaluating long-term complications has become increasingly important. First, the risk of a second malignancy has increased; contralateral testicular cancer is highest, between 2-5%, during the first 15 years (EBM level 3b). 63 Other second malignancies are carcinomas in prior radiation fields, and myelodysplasia or leukemia are often associated with etoposide dose (EBM level 3a). 27, 64 Cases of leukemia after cumulative doses of etoposide < 2 g have a reported incidence of 0.6%, and incidence is 2% if etoposide dose is ≥ 2 g (EBM level 3a) 64 (our patient received a total of 3,175 mg).
Second, there is the issue of medical late toxicity of chemotherapy. Cisplatin can cause renal dysfunction with a decreasing glomerular filtration rate (EBM level 3b) 65 and high-frequency hearing loss in 20-40% of patients (EBM level 3b). 66 Gonadal dysfunction is common in patients treated with orchiectomy only. Bleomycin can cause pulmonary fibrosis (approximately 5%; EBM level 3b 67 
)
5,67 and Raynaud's phenomenon (EBM level 3b). 68 The risks of cardiovascular disease (EBM level 3b) 28 and metabolic syndrome (EBM level 3b) 29 are also increased and should be actively monitored. Third, there are late psychosocial effects among GCT survivors. These include fear of recurrence, survivor guilt, sleep disturbance, cognitive dysfunction, anxiety or depression, difficulty forming relationships, and sexual dysfunction (EBM level 3b).
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Conclusion
We have presented a case with far-advanced embryonal carcinoma (stage IIIC) treated with current evidence-based therapy that has had very good results. Survival rates with modern therapy in GCT are high. EP × 4 or BEP × 3 is standard therapy for patients with good-risk features, and the cure rate is approximately 90%. Post-chemotherapy resection of all residual masses shown on imaging studies is advised if technically feasible, but there are some controversial issues. BEP × 4 is the standard therapy for intermediate-or poor-prognosis groups. Approximately 75% of patients in the intermediate-risk group and 45% of patients in the poor-risk group achieve a durable complete remission with these therapies. Patients requiring secondor third-line treatment are managed with TIP, VIP, VeIP, high-dose chemotherapy regimens, or a clinical trial. Finally, with the high rate of survival, quality care must include attention to the long-term outcomes of these young adult patients.
